business
Moderna's Stock Soars Following Cancer Vaccine Success; Estee Lauder Gains on Strong Earnings
19 Ağustos 2026Bloomberg
- Moderna's shares soared by 101%, marking its largest intraday gain ever, following promising results from a late-stage trial of its personalized cancer vaccine in collaboration with Merck & Co. The trial demonstrated significant reductions in melanoma recurrence and potential prevention of tumor spread.
- Meanwhile, Estee Lauder's stock also rose after surpassing earnings expectations for the fourth quarter, with optimistic guidance for fiscal 2027. In contrast, La-Z-Boy's shares fell due to disappointing sales forecasts.
- The stock market is often influenced by significant corporate announcements, especially in the biotech and consumer goods sectors. Moderna's breakthrough in cancer treatment could have far-reaching implications for both patient outcomes and the company's valuation.
- The dramatic rise in Moderna's stock reflects a growing investor confidence in innovative cancer treatments, particularly personalized medicine. The successful trial results not only enhance the company's market position but also signal a potential shift in treatment paradigms for melanoma.
NewsAI özeti
This article is for informational purposes only and does not constitute financial advice. Please consult a financial advisor for investment decisions.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.